

# Robert Zeillinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/847708/publications.pdf>

Version: 2024-02-01

220  
papers

8,564  
citations

38742

50  
h-index

69250

77  
g-index

222  
all docs

222  
docs citations

222  
times ranked

11988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer. <i>Investigational New Drugs</i> , 2022, 40, 215-223.	2.6	4
2	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. <i>Cancers</i> , 2022, 14, 1780.	3.7	4
3	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. <i>Cancers</i> , 2022, 14, 24.	3.7	25
4	Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4.	3.7	10
5	Patient satisfaction after breast cancer surgery. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 6-13.	1.9	11
6	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613.	3.7	10
7	BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. <i>Genes</i> , 2021, 12, 969.	2.4	3
8	Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 1225.	2.5	12
9	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 5865.	3.7	3
10	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451.	2.8	10
11	Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines. <i>Investigational New Drugs</i> , 2020, 38, 946-955.	2.6	8
12	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2519.	3.7	3
13	Gene Expression of Kallikreins in Breast Cancer Cell Lines. <i>Anticancer Research</i> , 2020, 40, 2487-2495.	1.1	4
14	miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3560-3573.	5.1	7
15	Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer. <i>Cells</i> , 2019, 8, 880.	4.1	26
16	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019, 28, 132-144.e3.	6.4	72
17	Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines. <i>Cancers</i> , 2019, 11, 114.	3.7	17
18	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 537-560.	4.1	19

#	ARTICLE	IF	CITATIONS
19	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patientsâ€” A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380.	1.4	11
20	Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1692-1698.	2.5	18
21	Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. <i>Analytical Chemistry</i> , 2018, 90, 13273-13279.	6.5	18
22	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 842.	3.5	5
23	Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. <i>Oncotarget</i> , 2018, 9, 812-823.	1.8	35
24	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. <i>Cancer Research</i> , 2017, 77, 1250-1260.	0.9	68
25	Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. <i>Oncology Letters</i> , 2017, 13, 4047-4054.	1.8	25
26	Small cell lung cancer: model of circulating tumor cell tumorspheres in chemoresistance. <i>Scientific Reports</i> , 2017, 7, 5337.	3.3	73
27	Comparison of a Prototype Reverse Hybridization Assay and MethyLight for Detection of SFRP2 Promotor Methylation in Fecal DNA. <i>International Journal of Biological Markers</i> , 2017, 32, 467-470.	1.8	2
28	EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. <i>Disease Markers</i> , 2017, 2017, 1-9.	1.3	37
29	Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. <i>PLoS ONE</i> , 2017, 12, e0189641.	2.5	8
30	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	1.8	42
31	PARP inhibition causes premature loss of cohesion in cancer cells. <i>Oncotarget</i> , 2017, 8, 103931-103951.	1.8	20
32	Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors. <i>Tumor Biology</i> , 2016, 37, 12079-12087.	1.8	18
33	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , 2016, 17, 643.	2.8	19
34	Simple laboratory score improves the preoperative diagnosis of adnexal mass. <i>Tumor Biology</i> , 2016, 37, 4343-4349.	1.8	10
35	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. <i>European Journal of Cancer</i> , 2016, 53, 51-64.	2.8	45
36	Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype. <i>Cell Adhesion and Migration</i> , 2016, 10, 360-367.	2.7	50

#	ARTICLE	IF	CITATIONS
37	Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies. <i>Hypertension in Pregnancy</i> , 2016, 35, 323-329.	1.1	6
38	Association of HER2 codon 655 polymorphism with ovarian cancer. <i>Tumor Biology</i> , 2016, 37, 7239-7244.	1.8	5
39	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patientsâ€”results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016.	1.8	23
40	The 811 C/T polymorphism in the 3â€™ untranslated region of the selenoprotein 15-kDa (Sep15) gene and breast cancer in Caucasian women. <i>Tumor Biology</i> , 2016, 37, 1009-1015.	1.8	10
41	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016, 36, 1015-22.	1.1	4
42	Correlation of circular RNA abundance with proliferation â€” exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis and normal human tissues. <i>Scientific Reports</i> , 2015, 5, 8057.	3.3	653
43	Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. <i>Cancer Letters</i> , 2015, 362, 218-228.	7.2	22
44	Circulating Tumor Cells in Small Cell Lung Cancer: Ex Vivo Expansion. <i>Lung</i> , 2015, 193, 451-452.	3.3	45
45	Lavage of the Uterine Cavity for Molecular Detection of MÃ¼llerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	1.6	87
46	Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. <i>Oncotarget</i> , 2015, 6, 17261-17275.	1.8	44
47	HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. <i>Anticancer Research</i> , 2015, 35, 5901-4.	1.1	5
48	HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. <i>Anticancer Research</i> , 2015, 35, 6667-70.	1.1	3
49	Known players, new interplay in atherogenesis: Chronic shear stress and carbamylated-LDL induce and modulate expression of atherogenic LR11 in human coronary artery endothelium. <i>Thrombosis and Haemostasis</i> , 2014, 112, 323-332.	3.4	12
50	HIF1&alpha; is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer &ndash; a study of the OVCAD Consortium. <i>OncoTargets and Therapy</i> , 2014, 7, 1563.	2.0	18
51	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 415-422.	1.4	38
52	Association of myeloperoxidase with ovarian cancer. <i>Tumor Biology</i> , 2014, 35, 141-148.	1.8	43
53	Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium. <i>Molecular Cancer</i> , 2014, 13, 67.	19.2	13
54	Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients â€” A study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014, 50, 99-110.	2.8	53

#	ARTICLE	IF	CITATIONS
55	Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. <i>Oncotarget</i> , 2014, 5, 462-472.	1.8	63
56	Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. <i>Journal of Ovarian Research</i> , 2013, 6, 42.	3.0	41
57	A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013, 13, 178.	2.6	29
58	PP057. ENOS14 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia – Analysis of five polymorphisms predisposing to cardiovascular disease in 279 caucasian and 241 african women. <i>Pregnancy Hypertension</i> , 2013, 3, 88.	1.4	3
59	The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma – Analysis of patient data in the prospective OVCAD study. <i>Gynecologic Oncology</i> , 2013, 131, 15-20.	1.4	99
60	Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013, 13, 422.	2.6	59
61	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 15-21.	1.4	107
62	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer – a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 38-43.	1.4	22
63	Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients. <i>Gynecologic Oncology</i> , 2013, 128, 245-251.	1.4	56
64	Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells. <i>International Journal of Oncology</i> , 2013, 42, 1383-1389.	3.3	30
65	Association of TAP Gene Polymorphisms and Risk of Cervical Intraepithelial Neoplasia. <i>Disease Markers</i> , 2013, 35, 79-84.	1.3	21
66	Determination of Tumor-infiltrating CD8+ Lymphocytes in Human Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 269-276.	1.4	9
67	The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-13.	2.5	46
68	Methylation status of <i>TUSC3</i> is a prognostic factor in ovarian cancer. <i>Cancer</i> , 2013, 119, 946-954.	4.1	48
69	Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium – OVCAD. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 268-275.	2.5	46
70	Duplex Reverse-Hybridization Assay for The Simultaneous Detection of KRAS/BRAF Mutations in FFPE-extracted Genomic DNA from Colorectal Cancer Specimens. <i>Disease Markers</i> , 2013, 34, 171-177.	1.3	7
71	The prostaglandin E2 transporting organic anion transporting polypeptide OATP4A1: A potential prognostic marker in colorectal cancer?. <i>Journal of Clinical Oncology</i> , 2013, 31, 430-430.	1.6	1
72	MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer. <i>Oncology Reports</i> , 2012, 27, 673-7.	2.6	4

#	ARTICLE	IF	CITATIONS
73	Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF- $\kappa$ B activation. <i>Annals of Oncology</i> , 2012, 23, 1795-1802.	1.2	60
74	A Miniaturized Ligand Binding Assay for EGFR. <i>International Journal of Proteomics</i> , 2012, 2012, 1-5.	2.0	1
75	Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA-IV: Analysis of the OVCAD Data. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 380-385.	2.5	91
76	Anticancer Effects of the Organosilicon Multidrug Resistance Modulator SILA 421. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 663-671.	1.7	3
77	The N-Terminally Truncated p53 Isoform $\Delta$ 40p53 Influences Prognosis in Mucinous Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 372-379.	2.5	36
78	Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between younger (<65) and elderly ( $\geq$ 65) patients. <i>European Journal of Cancer</i> , 2012, 48, 2962-2968.	2.8	25
79	Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium. <i>Molecular Cancer</i> , 2012, 11, 69.	19.2	35
80	Fibroblast growth factor receptor 4 gene ( <i>FGFR4</i> ) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. <i>International Journal of Cancer</i> , 2012, 131, E586-91.	5.1	29
81	Relaxin and gonadal steroid receptors in uterosacral ligaments of women with and without pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2012, 23, 495-500.	1.4	16
82	Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium. <i>Cancer Science</i> , 2012, 103, 1334-1341.	3.9	59
83	Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5034-5034.	1.6	0
84	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5071-5071.	1.6	1
85	$\Delta$ 133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 1593-1599.	6.4	40
86	Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: Relevance for paclitaxel transport. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 417-426.	5.6	73
87	<i>KRAS</i> mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridisation assay. <i>Journal of Clinical Pathology</i> , 2011, 64, 252-256.	2.0	9
88	Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer. <i>Oncology Reports</i> , 2011, 26, 1037-45.	2.6	31
89	Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. <i>Gynecologic Oncology</i> , 2011, 121, 537-541.	1.4	32
90	Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. <i>Acta Oncologica</i> , 2011, 50, 700-710.	1.8	213

#	ARTICLE	IF	CITATIONS
91	Anticancer activity and mode of action of titanocene C. <i>Investigational New Drugs</i> , 2011, 29, 607-614.	2.6	24
92	Expression of p16 protein and epidermal growth factor receptor in patients with adenocarcinoma of the uterine cervix: an immunohistochemical analysis. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 611-616.	1.7	5
93	Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: Proof of concept. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 100-111.	1.5	67
94	Clinical Relevance of TAp73 and $\hat{I}^{\text{Np73}}$ Protein Expression in Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 527-531.	1.4	11
95	hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7816-7827.	7.0	37
96	A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 850-860.	4.1	63
97	Prognostic Assessment and Adjuvant Treatment Strategies Within Early-Stage, Sporadic Triple Negative Breast Cancer Patients. <i>Cancer Investigation</i> , 2011, 29, 180-186.	1.3	6
98	Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2011, 12, 8530-8538.	4.1	4
99	Association of C-reactive protein (CRP) gene polymorphisms, serum CRP levels and cervical cancer prognosis. <i>Anticancer Research</i> , 2011, 31, 2259-64.	1.1	17
100	Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. <i>BMC Cancer</i> , 2010, 10, 666.	2.6	96
101	Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. <i>BMC Cancer</i> , 2010, 10, 682.	2.6	21
102	ABC transporter gene expression in benign and malignant ovarian tissue. <i>Gynecologic Oncology</i> , 2010, 117, 198-201.	1.4	58
103	BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF- $\hat{A}$ treatment. <i>Gynecologic Oncology</i> , 2010, 117, 189-197.	1.4	43
104	Drug resistance in ovarian cancer: Biomarkers and treatments. <i>Gynecologic Oncology</i> , 2010, 117, 149-151.	1.4	0
105	Alternative splicing of p53 and p73: the novel p53 splice variant p53 $\hat{I}$ is an independent prognostic marker in ovarian cancer. <i>Oncogene</i> , 2010, 29, 1997-2004.	5.9	72
106	Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 107.	2.7	2
107	New and potential clinical applications of KRAS as a cancer biomarker. <i>Expert Opinion on Medical Diagnostics</i> , 2010, 4, 383-395.	1.6	7
108	Circulating tumor cells in metastatic colorectal cancer: Efficacy and feasibility of different enrichment methods. <i>Cancer Letters</i> , 2010, 293, 117-123.	7.2	46

#	ARTICLE	IF	CITATIONS
109	Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. <i>Anticancer Research</i> , 2010, 30, 1341-5.	1.1	33
110	In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. <i>Metal-Based Drugs</i> , 2009, 2009, 1-11.	3.8	22
111	KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. <i>BMC Cancer</i> , 2009, 9, 111.	2.6	80
112	The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer – a multicenter study. <i>BMC Cancer</i> , 2009, 9, 78.	2.6	16
113	A prognostic gene expression index in ovarian cancer – validation across different independent data sets. <i>Journal of Pathology</i> , 2009, 218, 273-280.	4.5	107
114	Sensitive Detection of KRAS Mutations in Archived Formalin-Fixed Paraffin-Embedded Tissue Using Mutant-Enriched PCR and Reverse-Hybridization. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 508-513.	2.8	37
115	Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. <i>Anti-Cancer Drugs</i> , 2009, 20, 559-572.	1.4	17
116	The prohibitin 3 – untranslated region polymorphism in patients with ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 137, 236-239.	1.1	7
117	Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 710-714.	7.0	174
118	Circulating Cell-Free DNA in Plasma of Locally Advanced Rectal Cancer Patients Undergoing Preoperative Chemoradiation: A Potential Diagnostic Tool for Therapy Monitoring. <i>Disease Markers</i> , 2008, 25, 159-165.	1.3	59
119	Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers. <i>Cancer Research</i> , 2007, 67, 11876-11885.	0.9	67
120	p16INK4a Expression in Invasive Vulvar Squamous Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 279-283.	1.2	28
121	The Lack of Laminin-5 as a Prognostic Marker in Low-Grade Cervical Squamous Intraepithelial Lesions. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 89-94.	1.4	4
122	Expression of the Human MTA1 Gene in Breast Cell Lines and in Breast Cancer Tissues. <i>Oncology Research</i> , 2007, 16, 465-470.	1.5	12
123	Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 898-901.	7.0	99
124	In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. <i>British Journal of Cancer</i> , 2007, 96, 485-491.	6.4	68
125	Vascular endothelial growth factor gene polymorphisms in ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 105, 385-389.	1.4	26
126	The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 333-342.	2.5	86



#	ARTICLE	IF	CITATIONS
127	Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. <i>Anticancer Research</i> , 2007, 27, 1527-30.	1.1	7
128	The -463G/A polymorphism in myeloperoxidase gene and cervical cancer. <i>Anticancer Research</i> , 2007, 27, 1531-5.	1.1	9
129	Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. <i>Fertility and Sterility</i> , 2006, 85, 462-467.	1.0	36
130	Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 151-155.	2.5	36
131	A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 506-510.	1.4	25
132	Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 512-517.	1.4	124
133	Expression of KLF5 is a Prognostic Factor for Disease-Free Survival and Overall Survival in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 2442-2448.	7.0	108
134	HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. <i>Oncology Reports</i> , 2005, 14, 737.	2.6	8
135	Polymorphisms within the Interleukin-1 Gene Family and Unexplained Late Intrauterine Fetal Death: A Multi-center Study. <i>American Journal of Reproductive Immunology</i> , 2005, 53, 132-135.	1.2	4
136	An Angiopoietin-2 gene polymorphism in unexplained intrauterine fetal death: a multi-center study. <i>Journal of Reproductive Immunology</i> , 2005, 65, 47-53.	1.9	5
137	Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 97, 514-518.	1.4	19
138	The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection. <i>Gynecologic Oncology</i> , 2005, 98, 211-216.	1.4	30
139	Five genes from chromosomal band 8p22 are significantly downregulated in ovarian carcinoma. <i>Cancer</i> , 2005, 104, 2417-2429.	4.1	105
140	Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. <i>Oncology Reports</i> , 2005, 13, 375.	2.6	13
141	Perturbation of the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIPL and Deregulation of the Functional Receptors DR4 and DR5. <i>Clinical Cancer Research</i> , 2005, 11, 8585-8591.	7.0	54
142	Contribution of Epigenetic Silencing of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer. <i>Molecular Cancer Research</i> , 2005, 3, 335-343.	3.4	133
143	An Interleukin-6 Gene Promoter Polymorphism and Unexplained Late Intrauterine Fetal Death: A Multicenter Study. <i>Journal of the Society for Gynecologic Investigation</i> , 2005, 12, 33-36.	1.7	4
144	Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo. <i>Clinical Cancer Research</i> , 2005, 11, 8372-8383.	7.0	89

#	ARTICLE	IF	CITATIONS
145	Interleukin-1 and Interleukin-6 Gene Polymorphisms and the Risk of Breast Cancer in Caucasian Women: Table 1.. <i>Clinical Cancer Research</i> , 2005, 11, 5718-5721.	7.0	103
146	A Common Interleukin-6 Promoter Polymorphism in Patients With Vulvar Cancer. <i>Journal of the Society for Gynecologic Investigation</i> , 2005, 12, 617-620.	1.7	13
147	A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. <i>Fertility and Sterility</i> , 2005, 83, 1565-1567.	1.0	9
148	Polymorphisms of the Nos3 gene and unexplained late intrauterine fetal death. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2005, 122, 151-155.	1.1	6
149	Biochip for K-ras Mutation Screening in Ovarian Cancer. <i>Clinical Chemistry</i> , 2005, 51, 784-787.	3.2	15
150	Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. <i>Oncology Reports</i> , 2005, 13, 375-87.	2.6	39
151	Identification of CRASH, a gene deregulated in gynecological tumors. <i>International Journal of Oncology</i> , 2004, 24, 33.	3.3	3
152	Transdominant $\beta$ -TAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo. <i>Cancer Research</i> , 2004, 64, 2449-2460.	0.9	129
153	A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis. <i>Gynecologic Oncology</i> , 2004, 92, 936-940.	1.4	24
154	Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. <i>Gynecologic Oncology</i> , 2004, 93, 686-690.	1.4	35
155	Loss of Heterozygosity on Chromosome 13q: Suggestion of a Candidate Tumor Suppressor Gene in Sporadic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 143-148.	2.5	6
156	CXCR4 is Expressed in Ductal Carcinoma in situ of the Breast and in Atypical Ductal Hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2004, 84, 247-250.	2.5	72
157	Genetic Polymorphisms Associated With Thrombophilia and Vascular Disease in Women With Unexplained Late Intrauterine Fetal Death: A Multicenter Study. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 42-44.	1.7	45
158	A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2004, 81, 1638-1641.	1.0	37
159	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. <i>Oncology Reports</i> , 2004, 11, 1281-6.	2.6	14
160	Comparison of p53 Mutational Status with mRNA and Protein Expression in a Panel of 24 Human Breast Carcinoma Cell Lines. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 37-46.	2.5	46
161	Identification of Genes Associated with the Invasive Status of Human Mammary Carcinoma Cell Lines by Transcriptional Profiling. <i>Tumor Biology</i> , 2003, 24, 189-198.	1.8	36
162	Role of p53 in G2/M cell cycle arrest and apoptosis in response to $\beta$ -irradiation in ovarian carcinoma cell lines. <i>International Journal of Oncology</i> , 2003, 22, 51.	3.3	8

#	ARTICLE	IF	CITATIONS
163	Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. <i>International Journal of Oncology</i> , 2003, 22, 1117.	3.3	26
164	Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. <i>Oncology Reports</i> , 2003, 10, 1551.	2.6	2
165	The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. <i>Oncology Reports</i> , 2003, 10, 1025.	2.6	16
166	Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. <i>Oncology Reports</i> , 2003, 10, 1981.	2.6	2
167	Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. <i>International Journal of Oncology</i> , 2003, 22, 51-7.	3.3	13
168	Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. <i>Oncology Reports</i> , 2003, 10, 405-10.	2.6	26
169	The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. <i>Oncology Reports</i> , 2003, 10, 1025-9.	2.6	38
170	An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. <i>Cancer Research</i> , 2003, 63, 3066-8.	0.9	71
171	Polymorphisms of the angiotensinogen gene, the endothelial nitric oxide synthase gene, and the interleukin-1beta gene promoter in women with idiopathic recurrent miscarriage. <i>Molecular Human Reproduction</i> , 2002, 8, 95-100.	2.8	47
172	Polymorphisms of the Interleukin-1 Gene Cluster and Ovarian Cancer. <i>Journal of the Society for Gynecologic Investigation</i> , 2002, 9, 386-390.	1.7	20
173	Genetic alterations in endometrial hyperplasia and cancer. <i>Cancer Letters</i> , 2002, 175, 205-211.	7.2	18
174	Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. <i>Cancer Letters</i> , 2002, 185, 79-85.	7.2	27
175	Expression Profiling of Mammary Carcinoma Cell Lines: Correlation of in vitro Invasiveness with Expression of CD24. <i>Tumor Biology</i> , 2002, 23, 139-145.	1.8	55
176	Expression of MUC1 splice variants in benign and malignant ovarian tumours. <i>International Journal of Cancer</i> , 2002, 100, 166-171.	5.1	42
177	No association between the human progesterone receptor gene polymorphism PROGINS and risk for ovarian carcinoma in Austrian women. <i>International Journal of Cancer</i> , 2002, 101, 203-203.	5.1	5
178	Polymorphisms of the Endothelial Nitric Oxide Synthase Gene in Ovarian Cancer. <i>Gynecologic Oncology</i> , 2002, 86, 134-137.	1.4	51
179	Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. <i>Breast Cancer Research and Treatment</i> , 2002, 71, 249-255.	2.5	77
180	Human Progesterone Receptor Gene Polymorphism PROGINS and Risk for Breast Cancer in Austrian Women. <i>Breast Cancer Research and Treatment</i> , 2002, 72, 131-137.	2.5	29

#	ARTICLE	IF	CITATIONS
181	Expression of MUC1 Splice Variants Correlates with Invasive Growth of Breast Cancer Cell Lines. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 211-219.	2.5	12
182	Tumor necrosis factor- $\beta$ promoter polymorphisms and endometriosis. <i>Journal of the Society for Gynecologic Investigation</i> , 2002, 9, 313-318.	1.7	36
183	Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. <i>Clinical Cancer Research</i> , 2002, 8, 2253-9.	7.0	65
184	Analysis of the human progesterone receptor gene polymorphism prognins in Austrian ovarian carcinoma patients. <i>International Journal of Cancer</i> , 2001, 95, 394-397.	5.1	40
185	Novel MUC1 Splice Variants Are Expressed in Cervical Carcinoma. <i>Gynecologic Oncology</i> , 2001, 83, 343-347.	1.4	29
186	High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2001, 129, 23-29.	1.0	35
187	Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage. <i>Human Reproduction</i> , 2001, 16, 1644-1647.	0.9	72
188	Loss of heterozygosity (LOH) atp53 is correlated with LOH atBRCA1 andBRCA2 in various human malignant tumors. <i>International Journal of Cancer</i> , 2000, 88, 319-322.	5.1	18
189	Detection of p53 Polymorphism at Codon 72 by PCR and Allele-specific Oligonucleotide Hybridization on Microtiter Plates. <i>Clinical Chemistry</i> , 2000, 46, 124-126.	3.2	8
190	p53-dependent radioresistance in ovarian carcinoma cell lines. <i>Cancer Letters</i> , 2000, 150, 191-199.	7.2	33
191	BRCA1 Gene Mutations in Sporadic Ovarian Carcinomas: Detection by PCR and Reverse Allele-specific Oligonucleotide Hybridization. <i>Clinical Chemistry</i> , 1999, 45, 976-981.	3.2	34
192	Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1999, 56, 91-97.	2.5	48
193	Expression of mucins and cytokeratins in ovarian cancer cell lines. <i>Cancer Letters</i> , 1999, 145, 133-141.	7.2	28
194	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. <i>British Journal of Cancer</i> , 1998, 77, 1870-1874.	6.4	61
195	A differential PCR system for the determination of CCND1 (Cyclin D1) gene amplification in head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 1998, 34, 257-260.	1.5	13
196	Cytosol concentrations of CD44 isoforms in breast cancer tissue. <i>International Journal of Cancer</i> , 1998, 79, 541-545.	5.1	10
197	Chromosome region 8p11-p21: Refined mapping and molecular alterations in breast cancer. , 1998, 22, 186-199.		55
198	Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. <i>Cancer Letters</i> , 1998, 130, 69-76.	7.2	33

#	ARTICLE	IF	CITATIONS
199	Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer. <i>Oncology</i> , 1997, 54, 475-481.	1.9	72
200	Estrogen Does Not Induce the Calcium-Dependent Nitric Oxide Synthase in Cultured Human Uterine Endothelial and Myometrial Smooth Muscle Cells. <i>Journal of Vascular Research</i> , 1997, 34, 281-288.	1.4	22
201	Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. , 1997, 74, 322-325.		22
202	Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival. , 1997, 74, 455-458.		132
203	Quantitative Determination of Gene Expression by Competitive Reverse Transcriptionâ€“Polymerase Chain Reaction in Degraded RNA Samples. <i>Analytical Biochemistry</i> , 1997, 251, 173-177.	2.4	30
204	PCR-Mediated Synthesis of Exogenous Competitors for Quantitative RT-PCR. <i>BioTechniques</i> , 1996, 20, 360-362.	1.8	12
205	Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. <i>British Journal of Cancer</i> , 1996, 74, 1423-1426.	6.4	24
206	Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 205-207.	2.5	48
207	Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 257-263.	2.5	15
208	Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. , 1996, 69, 247-253.		158
209	Association of allelic losses on human chromosomal arms 11q and 16q in sporadic breast cancer. , 1996, 69, 307-311.		11
210	DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. <i>British Journal of Cancer</i> , 1996, 74, 1984-1989.	6.4	65
211	Quantitative detection of reverse transcriptase-PCR products by means of a novel and sensitive DNA stain.. <i>Genome Research</i> , 1995, 4, 234-238.	5.5	184
212	Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. <i>British Journal of Cancer</i> , 1995, 71, 1292-1296.	6.4	43
213	Fetal fibronectin as a marker to predict the onset of term labor and delivery. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 134-137.	1.3	41
214	Fetal fibronectin as a selection criterion for induction of term labor. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 1513-1517.	1.3	44
215	Patterns of dna amplification at band q13 of chromosome 11 in human breast cancer. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 42-48.	2.8	85
216	Patterns of allele losses suggest the existence of five distinct regions of loh on chromosome 17 in breast cancer. <i>International Journal of Cancer</i> , 1994, 56, 193-199.	5.1	66

#	ARTICLE	IF	CITATIONS
217	HER-2 oncogene amplification and overall survival of breast carcinoma patients. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1990, 26, 946-949.	0.7	19
218	Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. <i>Oncology Reports</i> , 0, , .	2.6	15
219	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. <i>Oncology Reports</i> , 0, , .	2.6	8
220	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1